Canadian Firm Seeks Approval to Manufacture MDMA and Other Psychedelics

Canadian Firm Seeks Approval to Manufacture MDMA and Other Psychedelics
High Times

A Canadian company that produces functional mushroom formulations for health and wellness has submitted a request to federal regulators that would allow it to manufacture MDMA and other synthetic psychedelic drugs. If the request made to Canada Health by Optimi Health seeking an amendment to its Controlled Substances Dealer’s license is approved, the company plans to manufacture MDMA, LSD, Mescaline, GHB and other psychedelics at its production facility in Princeton, British Columbia. Optimi Health Corporation is a Canadian firm that produces psilocybin and other functional formulations at its two plants in British Columbia following the European Union’s standards for good manufacturing practices (EU-GMP). Operating under a vertically integrated business model, the company is engaged in the cultivation, extraction, processing, and distribution of functional and psychedelic mushroom products at its two facilities in Princeton, which cover a combined total of 20,000 square feet. The company noted that with its major capital expenditures now completed, Optimi Health plans to expand its product offerings to include a wide variety of synthetic psychedelic compounds, leveraging its state-of-the-art cultivation facility and analytical lab in the process. The move aligns with the company’s transition to commercialization through standardized psychedelic drug research, testing, and product development via approved clinical trials and exemption-based applications. Growing Market for Psychedelics Optimi Health noted that ongoing large-scale studies including Phase III clinical trials into MDMA sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) and a move to decriminalize drugs in British Columbia have led to an increased demand for psychedelics. “Since our inception, Optimi has received a steadily increasing volume of inquiries related to the production of synthetic psychedelics from stakeholders within the sector, made all the more timely by recent developments,” Optimi Health chief science officer Justin Kirkland said in a statement from the company. “Our analytical laboratories were…

Excerpt only …
READ MORE BELOW
Source : Canadian Firm Seeks Approval to Manufacture MDMA and Other Psychedelics

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.